<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223284</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01909;me19ChristCrain</org_study_id>
    <nct_id>NCT04223284</nct_id>
  </id_info>
  <brief_title>Olfactory Odour Stimulation for Metabolism Control</brief_title>
  <acronym>OLFAMET</acronym>
  <official_title>Olfactory Odour Stimulation for Metabolism Control - the &quot;OLFAMET-Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this preliminary short-term study it is investigated, whether a short olfactory
      stimulation with D-Limonene leads to an acute improvement of glucose metabolism in patients
      with obesity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of area under blood glucose curve (AUBGC)</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections: 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>area under the blood glucose curve (AUBGC) during a mixed-meal test after stimulation with D-Limonene compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUBGC</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections: 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>AUBGC during a mixed-meal test after stimulation with SLVO compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS score)</measure>
    <time_frame>Time Frame: baseline VAS score (timepoint 0) and VAS scores will be evaluated after 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>VAS scores on hunger, appetite, nausea, mood, and hedonics of odour and/or taste of the mixed-meal shake, where 0 equals none, and 10 the maximum of each category</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma insulin levels</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections: 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma insulin levels (mIU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma peak glucose levels</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections: 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma peak glucose levels (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of glucagon-like peptide 1 (GLP-1)</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections after 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma levels of GLP-1 (pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of gastric inhibitory polypeptide (GIP)</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections after 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma levels of GIP (pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of Ghrelin</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections after 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma levels of Ghrelin (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of Leptin</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections after 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma levels of Leptin (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of Peptide YY (PYY)</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections after 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma levels of PYY (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of Glucagon</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections after 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma levels of Glucagon (pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma Levels of Interleukin-6</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections after 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma Levels of Interleukin-6 (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma Levels of C-reactive protein</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections after 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma Levels of C-reactive protein (μg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of lipids like LDL-cholesterine, total cholesterine, triglycerides</measure>
    <time_frame>Time Frame: baseline blood exam (timepoint 0) and further blood collections: 5, 15, 30, 60, 90 and 120 minutes after drinking a standardized mixed-meal solution</time_frame>
    <description>Plasma levels of lipids (mmol/L) like LDL-cholesterine, total cholesterine, triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Blood pressure and heart rate will be measured at the following times: baseline (timepoint 0) and 30, 60, 120 minutes drinking a standardized mixed-meal solution</time_frame>
    <description>Heart rate (heart beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Blood pressure and heart rate will be measured at the following times: baseline (timepoint 0) and 30, 60, 120 minutes drinking a standardized mixed-meal solution</time_frame>
    <description>blood pressure (mm Hg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Experimental1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the Cross-Over study, patients will be randomly assigned to one of the arms:
Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with D-Limonene at visit 2 and olfactory Stimulation with lavender oil (SLVO) at visit 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the Cross-Over study, patients will be randomly assigned to one of the arms:
Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with SLVO at visit 2 and olfactory Stimulation with D-Limonene at visit 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D-Limonene</intervention_name>
    <description>Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes</description>
    <arm_group_label>Experimental1</arm_group_label>
    <arm_group_label>Experimental2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SLVO</intervention_name>
    <description>Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes</description>
    <arm_group_label>Experimental1</arm_group_label>
    <arm_group_label>Experimental2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-70 years

          -  Obesity (BMI ≥35 kg/m2)

          -  Written informed consent

          -  Normosmia (defined by sniffin Sticks test)

        Exclusion Criteria:

          -  Known allergy to D-Limonene, citrus fruits, citrus flavours, SLVO

          -  Regular smoking

          -  Current illicit drug abuse including daily marijuana and cannabidiol (CBD) consumption
             (alcohol ≤2 drinks per day allowed)

          -  Diabetes mellitus

          -  Pre-Treatment with insulin sensitizing drugs including GLP-1 analogues

          -  History of neurodegenerative diseases, severe head trauma

          -  Severe renal impairment (e.g. estimated glomerular filtration rate &lt;30 ml/min/m2)

          -  Known liver cirrhosis or other severe liver impairment

          -  Acute upper respiratory tract infection

          -  Uncontrolled dysthyroidism

          -  Uncontrolled hypertension

          -  Regular use of psychopharmaceutic drugs

          -  Patient aims to start a new diet or exercise program during the study

          -  Bariatric surgery

          -  Pregnancy/Lactation

          -  Symptoms of menopause

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc.

          -  Participation in an interventional study within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katharina Timper, Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology, Diabetology and Metabolism, University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katharina Timper, Dr. med</last_name>
    <phone>061 328 57 42</phone>
    <email>katharina.timper@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Milica Popovic, Dr. med</last_name>
    <phone>061 328 56 92</phone>
    <email>milica.popovic@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic for Intensive Care Medicine, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Timper, Dr. med</last_name>
      <phone>061 328 57 42</phone>
      <email>katharina.timper@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Milica Popovic, Dr. med</last_name>
      <phone>061 328 56 92</phone>
      <email>milica.popovic@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Antje Welge-Lüssen, Prof. Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>D-limonene</keyword>
  <keyword>lavender oil (SLVO)</keyword>
  <keyword>Olfactory stimulation</keyword>
  <keyword>Obesity</keyword>
  <keyword>glucose metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

